Literature DB >> 29731529

Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

Yifei Sun1, Chiung-Yu Huang2, Mei-Cheng Wang1.   

Abstract

Benefit-risk assessment is a crucial step in medical decision process. In many biomedical studies, both longitudinal marker measurements and time to a terminal event serve as important endpoints for benefit-risk assessment. The effect of an intervention or a treatment on the longitudinal marker process, however, can be in conflict with its effect on the time to the terminal event. Thus, questions arise on how to evaluate treatment effects based on the two endpoints, for the purpose of deciding on which treatment is most likely to benefit the patients. In this article, we present a unified framework for benefit-risk assessment using the observed longitudinal markers and time to event data. We propose a cumulative weighted marker process to synthesize information from the two endpoints, and use its mean function at a prespecified time point as a benefit-risk summary measure. We consider nonparametric estimation of the summary measure under two scenarios: (i) the longitudinal marker is measured intermittently during the study period, and (ii) the value of the longitudinal marker is observed throughout the entire follow-up period. The large-sample properties of the estimators are derived and compared. Simulation studies and data examples exhibit that the proposed methods are easy to implement and reliable for practical use. Supplemental materials for this article are available online.

Entities:  

Keywords:  Kernel smoothing; Longitudinal marker process; Multiple event process; Survival analysis

Year:  2017        PMID: 29731529      PMCID: PMC5935274          DOI: 10.1080/01621459.2016.1180988

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  21 in total

1.  Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators.

Authors:  Y Huang; T A Louis
Journal:  Lifetime Data Anal       Date:  1999-09       Impact factor: 1.588

2.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

3.  Efficient estimation of the distribution of quality-adjusted survival time.

Authors:  H Zhao; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

4.  Quality adjusted survival analysis with repeated quality of life measures.

Authors:  P P Glasziou; B F Cole; R D Gelber; J Hilden; R J Simes
Journal:  Stat Med       Date:  1998-06-15       Impact factor: 2.373

5.  Mixture models for the joint distribution of repeated measures and event times.

Authors:  J W Hogan; N M Laird
Journal:  Stat Med       Date:  1997 Jan 15-Feb 15       Impact factor: 2.373

6.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

Review 7.  Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Authors:  J D Neaton; D N Wentworth; F Rhame; C Hogan; D I Abrams; L Deyton
Journal:  Stat Med       Date:  1994 Oct 15-30       Impact factor: 2.373

8.  Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits.

Authors:  P A Murtaugh; E R Dickson; G M Van Dam; M Malinchoc; P M Grambsch; A L Langworthy; C H Gips
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

9.  Statistical inference methods for recurrent event processes with shape and size parameters.

Authors:  Mei-Cheng Wang; Chiung-Yu Huang
Journal:  Biometrika       Date:  2014-09-01       Impact factor: 2.445

10.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.